cycloserine has been researched along with Cognition Disorders in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Billiras, RI; Dekeyne, A; Fone, KCF; Gobert, A; Millan, MJ; Rivet, JM; Sicard, DI; Watson, DJG | 1 |
| Belzung, C; Griebel, G; Philbert, J | 1 |
| Chen, CY; Chou, SJ; Chou, WH; Chuang, HC; Hsueh, YP; Huang, TN; Wang, HF | 1 |
| Bello, I; Cain, CK; Creedon, T; Goff, DC; Laska, E; McCue, M; Tang, DI | 1 |
| Kallogjeri, D; Krings, JG; Lenze, EJ; Nicklaus, J; Piccirillo, JF; Rodebaugh, TL; Wineland, A | 1 |
| Cather, C; Evins, AE; Goff, DC; Gottlieb, JD; Green, MF; Otto, MW; Raeke, L; Schoenfeld, D; Walsh, J | 1 |
| Frase, L; Nissen, C; Normann, C | 1 |
| Brown, P; Daly, EJ; Falk, WE; Gunther, J; Tsai, GE | 1 |
| Angrist, B; Bugarski-Kirola, D; Corwin, J; Duncan, EJ; Efferen, TR; Gonzenbach, S; Kunzova, A; Negi, S; Peselow, E; Rotrosen, JP; Schwartz, MP; Stephanides, M; Szilagyi, S | 1 |
| Buchanan, RW; Carpenter, WT; Gold, JM; Heresco-Levy, U; Javitt, DC; Marder, SR; McMahon, RP; Schooler, NR | 1 |
| Katz, MH | 1 |
| Benes, C; Cutler, NR; Fakouhi, TD; Hantsburger, G; Herting, R; Jhee, SS; Schwartz, P; Sramek, JJ; Swabb, EA | 1 |
| Coyle, JT; Falk, WE; Gunther, J; Tsai, GE | 1 |
| Javitt, DC | 1 |
| Schmidt, WJ; Schuster, GM | 1 |
4 review(s) available for cycloserine and Cognition Disorders
| Article | Year |
|---|---|
Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives.
Topics: Brain; Central Nervous System Stimulants; Cognition Disorders; Cycloserine; Emotions; Humans; Interpersonal Relations; Learning; Mental Disorders; Oxytocin; Psychotherapy | 2012 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Glycine; Humans; Male; Middle Aged; Neuropsychological Tests; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Severity of Illness Index | 2004 |
Effect of HIV treatment on cognition, behavior, and emotion.
Topics: Acquired Immunodeficiency Syndrome; Cognition Disorders; Cycloserine; Didanosine; Humans; Mental Disorders; Mood Disorders; Stavudine; Zidovudine | 1994 |
Treatment of negative and cognitive symptoms.
Topics: Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Glycine; Humans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Schizophrenic Psychology; Serine; Treatment Outcome | 1999 |
7 trial(s) available for cycloserine and Cognition Disorders
| Article | Year |
|---|---|
d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Topics: Acoustic Stimulation; Adult; Antimetabolites; Cognition Disorders; Cognitive Behavioral Therapy; Cycloserine; Discrimination, Psychological; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Single-Blind Method | 2014 |
A novel treatment for tinnitus and tinnitus-related cognitive difficulties using computer-based cognitive training and D-cycloserine.
Topics: Adult; Aged; Cognition Disorders; Cognitive Behavioral Therapy; Cycloserine; Double-Blind Method; Feasibility Studies; Female; Humans; Male; Middle Aged; Patient Compliance; Tinnitus | 2015 |
Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Cycloserine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Placebos; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2008 |
Effects of D-cycloserine on negative symptoms in schizophrenia.
Topics: Affect; Antimetabolites; Antipsychotic Agents; Cognition Disorders; Cycloserine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Glycine; Humans; Male; Middle Aged; Neuropsychological Tests; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Severity of Illness Index | 2004 |
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Topics: Adolescent; Adult; Cognition Disorders; Cycloserine; Double-Blind Method; Excitatory Amino Acid Agents; Female; Follow-Up Studies; Glycine; Humans; Male; Middle Aged; Neuropsychological Tests; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2007 |
Evaluation of cycloserine in the treatment of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antibiotics, Antitubercular; Cognition Disorders; Cycloserine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Placebos | 1995 |
Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
Topics: Aged; Alzheimer Disease; Cognition; Cognition Disorders; Cycloserine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycine; Humans; Male; Memory; Middle Aged; Placebos; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate | 1999 |
5 other study(ies) available for cycloserine and Cognition Disorders
| Article | Year |
|---|---|
Comparative Pro-cognitive and Neurochemical Profiles of Glycine Modulatory Site Agonists and Glycine Reuptake Inhibitors in the Rat: Potential Relevance to Cognitive Dysfunction and Its Management.
Topics: Amino Acids; Animals; Autism Spectrum Disorder; Cognition; Cognition Disorders; Cycloserine; Dose-Response Relationship, Drug; Freezing Reaction, Cataleptic; Glycine; Glycine Agents; Male; Memory, Short-Term; Motor Activity; Neurotransmitter Uptake Inhibitors; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Glycine; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Sarcosine; Schizophrenia; Scopolamine; Serine; Social Behavior | 2020 |
The CRF₁ receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D-cycloserine.
Topics: Animals; Behavior, Animal; Cognition Disorders; Cycloserine; Electroshock; Hippocampus; Hydrocarbons, Halogenated; Male; Mice; Paroxetine; Receptors, Corticotropin-Releasing Hormone; Selective Serotonin Reuptake Inhibitors; Stress, Psychological; Thiazines; Time Factors | 2013 |
Tbr1 haploinsufficiency impairs amygdalar axonal projections and results in cognitive abnormality.
Topics: Amygdala; Animals; Antimetabolites; Axons; Cadherins; Cognition Disorders; Contactin 2; Cycloserine; Disease Models, Animal; DNA-Binding Proteins; Exploratory Behavior; Gene Expression Profiling; Gene Expression Regulation; Magnetic Resonance Imaging; Maze Learning; MEF2 Transcription Factors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Nerve Tissue Proteins; Netrins; Oligonucleotide Array Sequence Analysis; Organ Culture Techniques; Proto-Oncogene Proteins c-fos; T-Box Domain Proteins | 2014 |
A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease.
Topics: Adolescent; Adult; Alzheimer Disease; Antimetabolites; Child; Cholinesterase Inhibitors; Cognition Disorders; Cycloserine; Donepezil; Drug Therapy, Combination; Humans; Indans; Neuropsychological Tests; Piperidines | 2002 |
D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task.
Topics: Analysis of Variance; Animals; Cognition Disorders; Cycloserine; Hippocampus; Male; Memory Disorders; Quinolinic Acid; Rats; Rats, Sprague-Dawley | 1992 |